Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

May 15 2012 - The ASCO Post

Ourania Antoniou on LinkedIn: Revumenib Shows Promise for Advanced

Biomedicines, Free Full-Text

Revumenib Shows Promise in Acute Leukemia - CancerConnect

ASH: Novel menin inhibitors show promise for patients with

Clinical Trial Results National Cancer Institute

National Cancer Institute (NCI) on LinkedIn: A new type of

I-131 apamistamab induces response among adults with advanced

Treatment National Cancer Institute

Therapeutic implications of menin inhibition in acute leukemias

MEN1 mutations mediate clinical resistance to menin inhibition